<DOC>
	<DOC>NCT00662740</DOC>
	<brief_summary>The primary objectives of this study are to assess bronchodilator efficacy as determined by FEV1, the effect on dyspnoea as determined by the BDI/TDI, the effect on health status as determined by the SGRQ and the effect on COPD exacerbations.</brief_summary>
	<brief_title>Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol PE Capsule) in COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criteria: Main: Diagnosis of COPD Postbronchodilator FEV1&lt;80% predicted and FEV1/FVC&lt;70% predicted Exclusion criteria: Main: Significant other diseases then COPD Recent MI Unstable or lifethreatening arrythmia requiring intervention or change in drug therapy Hospitalisation for cardiac failure in past year History of asthma</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>